Samil Enterprise

Samil Enterprise was founded in 1958 and listed on KOSDAQ in 1992; it built early technical capability through construction work for the US Army in Korea and later earned recognition for plant construction across the Ulsan and Yeocheon industrial complexes.

Its core business is building construction covering schools, hospitals, factories and offices, alongside civil engineering work such as roads, ports and bridges. By revenue mix, private-sector building construction accounts for roughly 83%, public civil engineering about 13%, and public building construction about 4%.

Clients span private corporations, hospital and school foundations, and local governments and public agencies, with recent notable private building orders including a new Yuhan Chemical plant in Hwaseong, an outpatient center and steel-frame parking expansion at Konkuk University Hospital, and a new construction project in Cheongdam-dong.

A company official once told the press that the firm operates as "a 100% order-driven business, so corporate investment cycles affect performance," underscoring how revenue depends on contract wins and construction progress.

As a small/mid-cap KOSDAQ general contractor, its construction capability scale is smaller than large listed builders, but it has secured contracts by maintaining trust-based relationships with specific clients over its long history.

In recent years, the order mix has shifted from public-sector-centered work toward private building projects, accompanied by a rising average contract size.

Consolidated revenue in 2025 came to KRW85.18bn, down 24.4% from KRW112.65bn in 2024, while operating profit rose 30.8% year-on-year to KRW7.39bn from KRW5.65bn, and net income attributable to owners increased 17.0% to KRW6.84bn from KRW5.84bn.

This appears to reflect cost discipline combined with a growing share of relatively higher-margin private building contracts even as top-line revenue contracted. Operating margin indeed improved for four consecutive years, from 3.4% in 2022 to 3.9% in 2023, 5.0% in 2024 and 8.7% in 2025.

Net income also rose steadily, from KRW2.49bn in 2022 to KRW3.84bn in 2023, KRW5.84bn in 2024 and KRW6.84bn in 2025, continuing a profit-recovery trend. Quarterly results, however, have been uneven.

Third-quarter 2025 revenue of KRW17.50bn came with operating profit of KRW1.88bn (margin of roughly 10.8%), before fourth-quarter revenue rose to KRW26.19bn while operating profit fell to KRW1.31bn (margin of roughly 5.0%).

First-quarter 2026 posted revenue of KRW20.13bn and operating profit of KRW1.52bn (margin of roughly 7.5%), and second-quarter 2026 revenue jumped to KRW38.33bn quarter-on-quarter, yet operating profit was only KRW1.15bn (margin of roughly 3.0%), showing revenue growth and margin improvement moving out of step.

On the cash flow side, operating cash flow swung from a net outflow of KRW4.6bn in 2023 to net inflows of KRW7.01bn in 2024 and KRW15.82bn in 2025, likely reflecting advance-payment inflows tied to the expanding order book.

The domestic construction industry is generally seen as passing through a phase of intensified order competition, driven by a combination of a soft real-estate market and rising raw-material and labor costs.

Public-sector order volumes tend to fluctuate significantly with fiscal conditions and policy direction, and small and mid-cap builders including Samil Enterprise have visibly shifted their order mix from public works toward private building projects.

Private building contracts tend to be larger in scale and often offer easier paths to profitability, which can create performance divergence between builders that secure such work and those that do not.

Compared with large listed contractors, Samil Enterprise's construction-capacity scale and capital base are smaller, but its low debt ratio and improving cash generation could be viewed as a relatively stable position within the sector.

Orders for quasi-public facilities such as schools and hospitals provide a relatively stable demand base, while recent wins in high-value residential and commercial projects such as the Cheongdam-dong development suggest a diversifying revenue mix.

The broader industry cycle still appears to carry downside pressure, making order quality and construction-management capability key differentiators for individual companies' results.

The order backlog stood at KRW198.3bn at end-2025, more than tripling from KRW60.7bn at end-2024, and the growing share of medium- to long-term projects running into 2026 and beyond is seen as providing a base for revenue to be recognized progressively over time.

Notable projects reflected in the backlog include the new Yuhan Chemical plant in Hwaseong, the outpatient center and steel-frame parking expansion at Konkuk University Hospital, and the Cheongdam-dong new-construction project.

This order expansion can be seen as part of the backdrop for the sharp quarter-on-quarter revenue increase in the second quarter of 2026, but the operating margin narrowed over the same period, suggesting either early-stage cost loading on new projects or a mix that includes relatively lower-margin work.

The company has previously explained that, given the order-driven nature of its business, future performance depends on real-estate and corporate-investment cycles and on securing further new orders, making the pace of additional order intake after the current backlog is worked through an important variable to monitor.

Whether the qualitative improvement in the backlog (weighted toward mid- to long-term, private-sector projects) continues, and how well margins can be defended through cost management, are likely to be the key variables for results from the second half of 2026 onward.